Document Detail


Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.
MedLine Citation:
PMID:  17636089     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate the efficacy of liraglutide, a new, stable, once-daily human analog of glucagon-like peptide-1, in a new animal model of obesity.
RESEARCH METHODS AND PROCEDURES: Liraglutide was administered subcutaneously once daily (7 microg/kg for 7 weeks) to six female obese Göttingen minipigs. Food intake and feeding patterns were monitored using a novel automated feeding system that allowed continuous recording of food intake.
RESULTS: Food intake was strongly suppressed. A steady-state level of reduced food intake was achieved within 3 weeks and was maintained for the remaining 4 weeks of the treatment period. During the 4-week steady-state period with liraglutide treatment, daily food intake was 7.3+/-0.3 megajoule (MJ) compared with 18.4+/-0.6 MJ in the pre-treatment period and 19.2+/-0.5 MJ in the post-treatment period (p<0.001). The food intake in the treatment period was equivalent to the amount of food that would have been offered to normal-weight pigs for maintenance. Body weight decreased 4.3+/-1.2 kg (4% to 5%) during the 7 weeks of treatment and increased 7.0+/-1.0 kg during the 7 weeks of post-treatment (p<0.01). Appetite suppression was quickly reversed within 4 days after termination of liraglutide administration.
DISCUSSION: Overall, liraglutide was well tolerated and had a profound and persistent anorectic effect that resulted in weight loss. These results, in conjunction with the previously established glucose-lowering efficacy of liraglutide, suggest that the anorectic actions of liraglutide will be very important in clinical trials of both obese patients with type 2 diabetes and obese non-diabetic patients.
Authors:
Kirsten Raun; Pia von Voss; Lotte Bjerre Knudsen
Related Documents :
18939959 - Gut hormones and appetite control.
16048669 - The prevalence and costs of obesity in the eu.
18987269 - Central control of body weight and appetite.
20390979 - Parents as health promoters: a theory of planned behavior perspective on the prevention...
18417649 - Leptin extends the anorectic effects of chronic pyy(3-36) administration in ad libitum-...
7030989 - Appetitive behavior after jejunoileal bypass.
21310449 - Factors affecting pharmacokinetics of benzimidazole anthelmintics in food-producing ani...
21770849 - Review of mycotoxin reduction in food and feed: from prevention in the field to detoxif...
15704239 - Comparison of the 2,2'-azinobis-3-ethylbenzotiazo-line-6-sulfonic acid (abts) and ferri...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Obesity (Silver Spring, Md.)     Volume:  15     ISSN:  1930-7381     ISO Abbreviation:  Obesity (Silver Spring)     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-07-19     Completed Date:  2007-10-26     Revised Date:  2013-05-13    
Medline Journal Info:
Nlm Unique ID:  101264860     Medline TA:  Obesity (Silver Spring)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1710-6     Citation Subset:  IM    
Affiliation:
Department of Pharmacy Research 3, Diabetes Pharmacology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Maaloev, Denmark. kira@novonordisk.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Appetite Depressants / therapeutic use*
Body Composition
Body Weight / drug effects
Disease Models, Animal
Energy Intake / drug effects*
Female
Glucagon-Like Peptide 1 / analogs & derivatives*,  physiology*,  therapeutic use
Obesity / drug therapy*
Swine
Swine, Miniature
Chemical
Reg. No./Substance:
0/Appetite Depressants; 839I73S42A/liraglutide; 89750-14-1/Glucagon-Like Peptide 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up.
Next Document:  Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects.